THERAPY DOSSIER · th-9549f65d68f9

Injectable EDC/NHS cross-linked recombinant human collagen type I (rHCI) and type III (rHCIII) matrices containing chondroitin sulfate C

Device

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31653830 ↗2019Mixed findings

Injectable human recombinant collagen matrices limit adverse remodeling and improve cardiac function after myocardial infarction.

MouseIschaemia-reperfusionCardiacC57BL/6 (Cx3cr1-EGFP mice used for monocyte tracking)Femalen = Three to fifteen mice per group as specified in figure lege…Intramyocardial injection via 27-G needle, ultrasound-guided closed-chest procedureFive equivolumetric intramyocardial injections of 10 uL eac…1 week after myocardial infarction, at the end of the proliferative phase

Model: Permanent ligation of the left anterior descending coronary artery via fourth intercostal thoracotomy

rHCI improved ejection fraction from 34.6 plus or minus 1.6% to 44.2 plus or minus 1.9% at 28 days, reduced scar size by about 37%, maintained remote wall thickness and increased border zone capillaries and pro-healing macrophages, whereas rHCIII preserved but did not improve function and PBS-treat…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…